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Introduction
In the world, diabetes has been one of the representative non-
communicable diseases (NCDs).1 The prevalence and incidence are 
increasing in developing and developed countries and districts.2 From 
medical and economic points of view, increasing diabetes has brought 
various crucial influences.3 As to diabetic therapy, some options have 
been continued for years such as oral hypoglycemic agents (OHAs) 
and also some injectable agents.4 
Among various topics concerning the treatment agents for 
diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-
1RAs) have been in focus for actual practice.5 After several years 
for recognizing the clinical effect of GLP-1RAs, the combined agent 
of GLP-1RA and basal insulin was introduced to medical treatment 
associated with more benefit involvement.6 Xultophy includes two 
agents of liraglutide and basal insulin degludec with a fixed ratio. It is 
often described as IDegLira.7
IDegLira reveals the beneficial efficacy from each agent.6 
Consequently, complementary effects are observed from liraglutide 
and degludec. The former can lower fasting blood glucose and the 
post-prandial glucose response. Further, the former can improve β-cell 
function, maintain the post-prandial insulin response and restore the 
cardioprotective properties.8 In contrast, the latter degludec can reduce 
the level of fasting blood glucose because of it can influence glucose 
level for long hours.9 
As to the fixed-ratio combination of IDegLira, there was a study of 
DUAL™ (Dual Action of Liraglutide and Insulin Degludec) clinical 
trial program.10,11 The safety and effect were investigated in a series 
of DUAL programs. They showed that the superior or noninferior 
glycemic control was found with several comparators, associated 
with the benefit for lower risk of hypoglycemia and weight gain in 
comparison with other insulin agents.12,13 
Regarding diabetic practice, authors and collaborators have 
continued a variety of research. They include low carbohydrate 
diet (LCD), calorie restriction (CR), meal tolerance test (MTT), 
continuous glucose monitoring (CGM), treatment of insulin, GLP-
1RA, Xultophy, and so on.14,15 Especially, Xultophy has been applied 
to patients with multiple problems and dialysis.16,17 Xultophy has been 
known to be clinically effective for patients with various diseased 
states such as renal insufficiency or chronic renal failure, or limited 
treatment options.18 This would be due to the beneficial efficacy of 
combined pharmacological agents. An impressive diabetic case was 
observed who has changed the treatment of multiple daily injection 
(MDI) insulin therapy to Xultophy only one injection per day. In this 




The case is a 82-year-old female patient with Type 2 Diabetes 
Mellitus (T2DM). She was pointed out to have diabetes at 60 years 
old. She has received DM treatment at another hospital in recent 
years. The treatment included Lantus XR 4 units, glimepiride 6mg, 
miglitol 150mg, vildagliptin 100mg, metformin 500mg per day, but 
her diabetic control was poor as HbA1c 10.2%.
She developed headache from Dec 23, 2020 cough and low back 
pain from Dec 25, 2020 and visited the hospital. As a treatment, she 
was treated with celecoxib but the symptoms did not relieved. Then, 
she visited another hospital on Jan 6 and was proved to be negative for 
PCR examination of COVID-19. 
She was referred to the Tokushima Red Cross Hospital (TRCH) and 
was diagnosed with empyema in the right lung and was hospitalized. 
The treatments included Tazobactam and Piperacillin Hydrate (TAZ / 
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Abstract
The case is an 82-year-old female patient with Type 2 Diabetes Mellitus (T2DM) for 22 
years. She developed right empyema in early January, 2021 and was treated by antibiotics 
and CT-guided drainage. After improving the status, she was transferred to Hayashi hospital, 
Tokushima, Japan. Treatment for T2DM was initially multiple daily insulin injection 
(MDI), but it could not continue because of injection several times a day by the family. 
Then, Xultophy was started once a day, which brought satisfactory glucose variability with 
lower doses. Consequently, Xultophy would be effective and useful agent from bio-psycho-
social points of view. 
Keywords: multiple daily insulin injection (MDI), Xultophy, Type 2 Diabetes Mellitus 
(T2DM), bio-psycho-social, multiple daily injection (MDI)
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PIPC) 2.25g (ZocinR) q 6hrs, and also CT-guided drainage procedure. 
The culture result from the abscess revealed the Streptococcus 
anginosus. The discharge from the drain was disappeared, then 
the drainage was removed on Jan 13, 2021. For diabetic status, 
serum C-peptide 0.62ng/mL was in lower value, suggesting insulin 
deficiency. Consequently, multiple daily insulin injection (MDI) was 
started with insulin human for 3 times and Lantus XR once. The 
patient was transferred to Hayashi hospital which is situated nearby 
TRCH on Jan 14, 2021.
Physical status
Vitals and consciousness showed unremarkable acute 
abnormalities. She revealed SpO2 level as 96% in room air. Chest 
showed that regular rate rhythm in the heart and rather weaker breath 
sound in right lung. Abdomen revealed flat and soft with ordinary 
bowel sound. No abnormalities were observed in neurological 
examination. 
Several examinations
Several examinations on admission were as follows: Chest X-P 
and chest CT scan revealed the presence of the Empyema in the right 
lung. The lesion was found at first in the size of 8.2cm x 4.6cm in the 
lower lobe of the right lung, which was reduced 7.1cm x 3.2cm in 7 
days. ECG showed unremarkable changes. 
The laboratory examination were in the following: RBC 3.11 x 106/
μL, Hb 10.0g/dL, Ht 29.7%, MCV 95.5 fL (80-98), MCH 32.2pg (27-
34), MCHC 33.7g/dL (31-36), WBC 5740/μL, Plt 30.5 x 104/μL, AST 
32U/L, ALT 23U/L, γ-GT 37U/L, ALP 94U/L, LDH 233U/L (100-
340), T-Bil 0.5mg/dL, TP 6.3g/dL, Alb 2.3g/dL, A/G ratio 0.79, Alb 
44.25 %, α1-glb 4.4%, α2-glb 12.2%, β-glb 10.4%, γ-glb 28.8%, CRP 
2.16mg/dL, BUN 13mg/dL, Cr 0.81mg/dL, eGFR 51mL/min/1.73m2, 
Na 136mEq/L, K 4.7mEq/L, Cl 101mEq/L, T-C 149mg/dL, HDL-C 
50mg/dL, LDL-C 84mg/dL, TG 67mg/dL.
Other specific tests revealed as follows: Urinalysis data; protein 
(-), glucose (-), urobilinogen (+/-), bilirubin (-) ketone bodies (2+), 
pH 7.5, occult blood (-), specific gravity 1.015, bacteria (+/-), urine 
C-peptide excretion 19.1μg/day (23-155), urinary albumin 5.4mg/day 
(2-20), tumor markers: CEA 3.9ng/ml, (-5.0), SLX 22.8U/mL, (-38), 
SCC Ag 0.8ng/mL (-1.5), CYFRA 1.5ng/mL (-3.5), NSE 9.4ng/mL 
(-16.3).
ADL status
Before the hospitalization, her ADL was self-reliant. She could 
move freely associated with grasping the handrail in slow pace. 
Current episode with treatment in the hospital has brought her power 
reduction of the legs. After the operation on January 7, she started 
rehabilitation from an early stage using a rehabilitation walker. The 
value of SpO2 during rehabilitation did not decrease keeping around 
94-96% in the room air, and her rehabilitation could be continued. 
With the treatment walker, she was able to walk 120 meters with 
light assistance. Basic movements were required mild to moderate 
assistance in usual ADL until January 13, and some improvements are 
expected in the future.
Medical problems
From mentioned above, the medical problems of this patient are 
summarized as follows: #1 empyema (right lung), #2 Type 2 diabetes 
mellitus (T2DM), #3 hypertension, #4 hyperlipidemia.
Related to these problems, current medication concerning 
#2,3,4 includes amlodipine besilate (AmlodineR) 5mg 1T, azilsartan 
(AzilvaR) 20mg 1T, atorvastatin (Lipitor R)10mg 1T and vonoprazan 
fumarate (TakecabR)10mg 1T.
Clinical progress
The patient with empyema was relieved by the administration 
of antibiotics and the procedure of drainage treatment. Regarding 
antibiotics, Tazobactam and Piperacillin Hydrate (TAZ/PIPC) were 
initially administered, and then amoxicillin hydrate, potassium 
clavulanate were administered for 2 weeks. In addition, carbocisteine 
500mg 3 Tablets was provided for facilitating the sputum discharge. 
From these combined treatments, empyema was completely cured.
The changes in various biomarkers with the clinical course were 
shown in Table 1. Among them, during Jan 6-14, leukocytosis was 
improved from 10520/μL to 5740/μL and elevated CRP was decreased 
from 18.1mg/dL to 2.2mg/dL. During Jan 14-Feb 17, total protein was 
increased from 6.3g/dL to 7.6g/dL and albumin was also increased 
from 2.3g/dL to 3.5g/dL.
Table 1 Changes in several biomarkers
  01/06 01/09 01/14 02/04 02/17
WBC (/μL) 10520 5720 5740 6340 5800
Hb (g/dL) 11 9.7 10 12.1 12.2
CRP (mg/dL) 18.1 6.8 2.2 0.27 0.3
TP (g/dL) - 6.1 6.3 - 7.6
Alb (g/dL) - 2.0 2.3 - 3.5
T-Bil (mg/dL) 0.7 0.5 0.5 0.7 0.5
AST (U/L) 35 29 32 23 36
Na (mEq/L) 130 138 136 136 138
K (mEq/L) 4.5 4.5 4.7 4.8 4.7
Cr (mg/dL) 0.7 0.8 0.8 0.6 0.7
Furthermore, the relationship between diurnal fluctuations in 
blood glucose and treatment for diabetes was summarized in Table 
2. Initially, blood glucose was measured four times a day and insulin 
treatment was performed by the sliding scale method. Multiple daily 
insulin injection (MDI) is ideal, but when this planning method was 
explained to the patient and families, it was proved to be difficult 
to carry out. Then, the treatment was changed to the injection of 
Xultophy once a day. The starting amount was 6 doses, and the profile 
of blood glucose became stable at 5 doses. The HbA1c level was 
initially 10.5%, but improved to 7.5% at the time of discharge in late 
February.
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Table 2 Progress of blood glucose and treatment
Date
Daily profile of blood glucose Treatment
Morning Noon Evening Night Rapid Lantas Xultophy
(mg/dL) (mg/dL) (mg/dL) (mg/dL) (unit) (unit) (doses)
Jan 16 172 179 277 244 3-3-5 4
23 118 213 234 220 2-4-4 6
29 111 203 176 215 2-4-3 7
30 66 138 178 248 0-2-3 8
31 101 168 140 214 2-3-2 8
Feb 1 69 204 197 235 6
4 62 157 201 228 6
8 124 178 5
11 108 169 5
15 103 169 5
18 78 230 5
22 101 256 5
25 113  224    5
Discussion
In this report, clinical effect and related matters of Xultophy were 
described and discussed, which has the combinations of GLP-1RA 
and basal-bolus insulin. There were some papers concerning the 
comparative study of basal insulin and Xultophy. In the investigations 
on Xultophy, DUAL studies have been known,10,11 which stands for 
Dual Action of Liraglutide and Insulin Degludec clinical trial program. 
Other previous outcomes of studies on Xultophy were generally 
aligned with those of DUAL studies. They include significant reduction 
of HbA1c value, decreasing trend of body weight, low risk episodes 
for hypoglycemia compared with standard baseline regimens.19 The 
basal-bolus treatment has been evaluated to be effective for glucose-
lowering method, but it shows higher ratio of hypoglycemia episodes 
in comparison with other anti-diabetes treatments.20 
As a reliable investigation, the European Xultophy Treatment 
Retrospective Audit (EXTRA) study was conducted in European 
region. In some of the real-word evidence (RWE) studies of EXTRA, 
there were significant decreases of HbA1c of 0.7% and weight 
reduction of 2.4kg for 6 months in the diabetic cases that changed 
from MDI to Xultophy.21 According to the recent study in 2021, 
patients with T2DM changed the treatment from basal-bolus insulin 
to Xultophy, in which they started at 16 doses.22 The participants were 
indicated to titrate the doses to maintain fasting glucose value at 90-
130mg/dL two times a week. They can adjust the doses for plus 2 or 
minus 2 doses when titrating. As a result, HbA1c level for half year 
was 7.4% vs 8.4% in Xultophy group and control group, respectively.22 
The authors’ group has practiced and researched primary care 
(PC) medicine and integrative medicine (IM) for long.23 Common 
perspectives for PC and IM would be patient-oriented medicine. 
Three important points have been found, which are bio-psycho-social 
aspects. As regard to these, the example of diabetic patient will be 
presented.24 
The first is bio-aspect. Due to the current status of glycemic 
variability, oral hypoglycemic agents (OHAs) are not sufficient, and 
newer injectable agents are required such as GLP-1RA or Xultophy. 
The second is psycho-aspect. Some diabetic patients cannot tolerate 
limited diet for long period. From this feeling, it is not possible to 
actually continue appropriate behavior suitable for diabetes.25 The 
third is social-aspect. There are several diabetic patients who can 
not maintain proper lifestyle due to various temptation from friends 
and others. Further, it may be difficult to obtain the understanding 
and cooperation of family members. As mentioned above, these bio-
psycho-social aspects will be used as the fundamental perspectives in 
actual medical practice and care in the future.
Regarding the social aspect of the patient, she is elderly and does 
not work in particular. Her home has two households in the same 
location. One is for the patient and her husband, and another is for his 
son and wife. During the daytime, both her son and wife are absent for 
working. So far, there has been no smooth communication between the 
two households.26 The patient’s personality keeps a certain distance 
from his son and wife from a social and psychological point of view.27
From psychological point of view, the nature of the patient has 
been rather stubborn. She has continued to spend her life for long 
as she likes. Some feud may be present between the patient and her 
son and wife. She does not want to be involved in various matters 
with the son. In fact, social and psychological factors may affect the 
relationship of personal communication and also insulin treatment.28
When she was transferred from TRCH, MDI were recommended 
for obtaining the ideal blood glucose control. Simultaneously, the 
insulin doses were decided by sliding scale method. However, the 
patient or the family cannot perform such complex way. The patient 
did not want to ask the procedure to her son, then MDI and/or sliding 
scale method were not possible for the patient and family.29
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Xultophy can contribute to the treatment for diabetic patients with 
difficult therapeutic process. The reason includes useful procedure 
that it can be injected once a day at any time of the day.7 It is beneficial 
points from medical, psychological and social points of view. There 
were also characteristics regarding the amount of dose that could 
be controlled. In European and North American countries, patients 
who are already given insulin will start Xultophy at 16 doses, and 
those who are naive for insulin will start Xultophy at 10 doses.8 
However, rather lower doses of Xultophy can be started in Japan. In 
our previous study, the cases with starting Xultophy from small doses 
were reported, which were sufficiently effective.16 Probable reasons 
for these phenomena include smaller body physique, relatively regular 
lifestyle and synergistic effect of high sensitivity for combined insulin 
and GLP-1RA.30
There is a limit to the investigation of this case report. The case 
had several complications besides diabetes for years, and currently 
developed lung infection, in which mutual influences were not 
completely clarified yet. Xultophy was applied for bio-psycho-social 
reasons and the glycemic response was stable. However, problems 
include relatively high blood sugar in the afternoon, with pending 
status in the future. Xultophy will applied to recommended treatment 
according to the general situations.31
In summary, a case of 82-year-old female with T2DM developed 
empyema. Her treatment was changed from MDI to Xultophy, and 
effective and simple injection brought her stable situation. From bio-
psycho-social points of view, some perspectives were described in 
this article. Current report will hopefully serve as a reference in the 
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